Cardiovascular Disease - Lipids

Changes/additions to materials:

Ezetimibe and cancer — reassuring data
As we have blogged, an analysis of post-marketing adverse event reports did not find any increased risk of cancer with ezetimibe▼ compared with statins, either alone or when taken in combination with simvastatin. Although these data are reassuring, it would seem sensible to use ezetimibe▼ only with caution because there is no published evidence of its benefit on clinically important outcomes such as cardiovascular events and its long-term safety is unknown. Prescribers should continue to use evidence-based statins (e.g. simvastatin 40mg/day) first-line in most patients who require a lipid-lowering agent.

A MeReC Bulletin on lipid-modifying treatment is now available. It:

• addresses the similarities and differences between NICE guidance for people with and without type 2 diabetes
• provides clarification on NICE’s recommendations regarding thresholds for intensifying treatment
• discusses the evidence base for high-intensity statins, for rosuvastatin and for ezetimibe▼, the reliability of single cholesterol measurements, and the side effects of statins.

Cardiovascular Disease - Lipids Patient Decision Aid

The patient decision aids on NPCi have been developed to help guide difficult decisions in which patients need to consider benefits versus risks. Decision aids prepare patients for decision making by increasing their knowledge about expected outcomes and personal values.

These documents are based on the best available evidence but are not a substitute for a discussion with a suitably skilled healthcare professional. Wherever possible we have used a simple pictorial format. We hope that their use in such discussions will result in better informed, patient-focussed decision making.

You can either choose to view the decision aid on the screen by clicking the 'flash' version or you can download and print a copy by clicking the 'PDF' version.